Literature DB >> 29861613

IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer.

Jingfeng Qian1, Fangxing Ji2, Xue Ye1, Hongyan Cheng1, Ruiqiong Ma1, Xiaohong Chang1, Chengchao Shou2, Heng Cui1.   

Abstract

OBJECTIVE: Ovarian cancer (OC) is one of the leading causes of death for female cancer patients. COC166-9 is an OC-specific monoclonal antibody and we have identified immunoglobulin γ-1 heavy chain constant region (IGHG1) as its antigen. We explore the function of IGHG1 in proliferation, apoptosis and motility of OC cells further in this research.
METHODS: IGHG1 expression in OC specimens was detected through immunohistochemistry. Real-time quantitative polymerase chain reaction (RT-qPCR) or western blotting assay was used to test IGHG1 expression in OC cells. Viability of OC cells was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Flow cytometry or western blotting assay was used to detect cell cycle and apoptosis. Cellular motility was analyzed by using transwell assay and the markers of epithelial-mesenchymal transition (EMT) were tested through immunoblots.
RESULTS: Although it exerts negligible effect on the viability and apoptosis of OC cells, IGHG1 could promote migration and invasion of malignant cells in vitro. Mechanistically, IGHG1 increases the expression of N-cadherin and Vimentin while decreases E-cadherin expression. Additionally, IGHG1 expression in OC specimens is higher relative to the paired normal counterparts. Further analysis demonstrates that the increased IGHG1 expression correlates positively with the lymph node metastasis of OC.
CONCLUSIONS: IGHG1 promotes the motility of OC cells likely through executing the EMT program. Increased IGHG1 expression in OC specimens is associated with the lymph node metastasis.

Entities:  

Keywords:  EMT; IGHG1; invasion; metastasis; ovarian cancer

Year:  2018        PMID: 29861613      PMCID: PMC5953964          DOI: 10.21147/j.issn.1000-9604.2018.02.11

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  25 in total

1.  Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.

Authors:  Q H Miow; T Z Tan; J Ye; J A Lau; T Yokomizo; J-P Thiery; S Mori
Journal:  Oncogene       Date:  2014-05-26       Impact factor: 9.867

Review 2.  Lymph node metastasis in stages I and II ovarian cancer: a review.

Authors:  M Kleppe; T Wang; T Van Gorp; B F M Slangen; A J Kruse; R F P M Kruitwagen
Journal:  Gynecol Oncol       Date:  2011-10-06       Impact factor: 5.482

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

4.  Annual report on status of cancer in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

5.  Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

Authors:  Russell Hogg; Michael Friedlander
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

6.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

Authors:  David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

7.  FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.

Authors:  Wen-Tai Chiu; Yu-Fang Huang; Huei-Yu Tsai; Chien-Chin Chen; Chang-Hwa Chang; Soon-Cen Huang; Keng-Fu Hsu; Cheng-Yang Chou
Journal:  Oncotarget       Date:  2015-02-10

8.  Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms.

Authors:  Zhaohui Liu; Ying Tong; Yuanlin Liu; Huaping Liu; Chundong Li; Yue Zhao; Yi Zhang
Journal:  Cancer Cell Int       Date:  2014-11-26       Impact factor: 5.722

9.  The EMT (epithelial-mesenchymal-transition)-related protein expression indicates the metastatic status and prognosis in patients with ovarian cancer.

Authors:  Masaaki Takai; Yoshito Terai; Hiroshi Kawaguchi; Keisuke Ashihara; Satoe Fujiwara; Tomohito Tanaka; Satoshi Tsunetoh; Yoshimichi Tanaka; Hiroshi Sasaki; Masanori Kanemura; Akiko Tanabe; Masahide Ohmichi
Journal:  J Ovarian Res       Date:  2014-07-27       Impact factor: 4.234

10.  Parasympathetic neurogenesis is strongly associated with tumor budding and correlates with an adverse prognosis in pancreatic ductal adenocarcinoma.

Authors:  Lingfu Zhang; Limei Guo; Ming Tao; Wei Fu; Dianrong Xiu
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

View more
  2 in total

1.  Ligands, Receptors, and Transcription Factors that Mediate Inter-Cellular and Intra-Cellular Communication during Ovarian Follicle Development.

Authors:  Beatriz Peñalver Bernabé; Teresa Woodruff; Linda J Broadbelt; Lonnie D Shea
Journal:  Reprod Sci       Date:  2020-01-14       Impact factor: 3.060

2.  Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging.

Authors:  Chen Zhang; Xinyu Ling; Yanxiu Guo; Cunzhong Yuan; Hongyan Cheng; Xue Ye; Ruiqiong Ma; Yinli Zhang; Yi Li; Xiaohong Chang; Beihua Kong; Tao Liu; Heng Cui
Journal:  Chin J Cancer Res       Date:  2019-08       Impact factor: 5.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.